Drug name
Last update: Oct 2026GS-3242+LEN
Developer(s)
Drug information
GS-3242 + lenacapavir
investigational
Small molecule
INSTI (Integrase Strand Transfer Inhibitor), Capsid inhibitor — INSTI+capsid inhibitor
Active / In Development (Phase 1/2/3)
Not provided
Unknown
Unknown
Therapeutic area(s)
- HIV
- Treatment
Administration route
Oral, Subcutaneous, Route of administration is being determined in the clinical program
Associated long-acting platforms
Aqueous drug particle suspension, Oral solid form
Use of drug
- Administered by a community health worker
- Administered by a nurse
- Administered by a specialty health worker
- To be determined
- Every 6 months
- Other/Variable/Unknown : To be determined
Dosage
to be determined
to be determined
to be determined
Not provided
Not provided
Related entries
Cabotegravir + Lenacapavir
lenacapavir + teropavimab + zinlirvimab
Lenacapavir 6-monthly
Lenacapavir Once-Yearly
MK-8591D (Islatravir and Lenacapavir)
Additional information
Developer(s)
Gilead
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Not provided
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL